





RealRate

PHARMACEUTICAL 2020

Xenetic Biosciences Inc. Rank 127 of 358



The relative strengths and weaknesses of Xenetic Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xenetic Biosciences Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 109% points. The greatest weakness of Xenetic Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 130%, being 94% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	11,090
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,415
Liabilities, Non-Current	0
Other Assets	10,456
Other Compr. Net Income	0
Other Expenses	3,283
Other Liabilities	2,919
Other Net Income	112
Other Revenues	17
Property and Equipment	0.76
Research and Development	4,889
Selling, General and Administrative Expense	4,731

Output Variable	Value in 1000 USD
Assets	21,547
Liabilities	4,334
Expenses	12,904
Revenues	17
Stockholders Equity	17,213
Net Income	-12,775
Comprehensive Net Income	-12,775
Economic Capital Ratio	130%